# Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

> **NCT00790036** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 742 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Everolimus Placebo

## Key facts

- **NCT ID:** NCT00790036
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-24
- **Primary completion:** 2016-06-15
- **Final completion:** 2016-06-15
- **Target enrollment:** 742 (ACTUAL)
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790036, "Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00790036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*